Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
|Articles|August 1, 1999
The American Journal of Managed Care
- August 1999
- Volume 5
- Issue 8
To Cover or Not to Cover: How to Decide?
Advertisement
Articles in this issue
about 27 years ago
A Model for Improving Coverage Policy Decisionsabout 27 years ago
The Impact of Relational Activities on HMO Organizational Outcomesabout 27 years ago
HIV Infection in Adults: A Therapeutic UpdateAdvertisement
Related to this article
Kidney Week 2026 abstracts show that AMKD progresses quickly in routine practice, with or without diabetes, despite background CKD therapy.
Insurance barriers were the top reason 4 in 10 people prescribed long-acting PrEP at a Missouri clinic never received it, an IDWeek 2026 poster found.
A retrospective study suggests strength exercise may be a safer option than endurance exercise for some people with ACM.
Infant flu protection from maternal vaccination varied by timing, while pediatric vaccination fell to 49.4%, experts report at IDWeek 2026.
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
The pilot pairs grocery stipends and community health worker support with members who have unmanaged diabetes and unmet social needs.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD
3
Uninsured Rate Rises to 11.2% as Coverage Erodes Before Medicaid Cuts
4
UPMC Health Plan's Food as Medicine Pilot for Members With Diabetes
5